Equities research analysts at RBC Capital raised their price target on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from $35.00 to $40.00 in a note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has a “sector perform” rating on the stock. RBC Capital’s target price suggests a potential downside of 2.20% from the company’s current price.

Separately, Commerzbank AG downgraded Fresenius Medical Care AG & Co. to a “hold” rating in a research report on Friday, May 29th. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the company. Fresenius Medical Care AG & Co. currently has an average rating of “Hold” and an average price target of $39.03.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded down 0.34% on Friday, reaching $40.90. The company had a trading volume of 97,639 shares. The company has a 50-day moving average of $42.55 and a 200 day moving average of $41.20. The stock has a market cap of $24.86 billion and a price-to-earnings ratio of 23.66. Fresenius Medical Care AG & Co. has a one year low of $32.40 and a one year high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last announced its earnings results on Thursday, July 30th. The company reported $0.40 earnings per share for the quarter, missing the Thomson Reuters consensus estimate of $0.42 by $0.02. The company earned $4.20 billion during the quarter, compared to analysts’ expectations of $4.13 billion. The business’s revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.42 earnings per share. On average, equities research analysts predict that Fresenius Medical Care AG & Co. will post $1.76 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...